Abstract
Ischemic mitral regurgitation (IMR) is one of the most challenging
complications of acute myocardial infarction (AMI) and chronic coronary
artery disease (CAD). The presence of IMR, irrespective of severity
significantly have a negative impact on the short and long-term outcomes
of patients with AMI and CAD. Nearly 25% of patients with AMI without
congestive heart failure (CHF) develop IMR and this number approaches
50% when CHF is present.